Biomedical subjects

Mark L Messonnier

Publications and source records attributed to Mark L Messonnier.

5 recordsLinked to original sources

PubMed2006

Economics and public health at CDC.

Economics is the study of decisions--the incentives that lead to them and the consequences that result from them--as they relate to present and future production, distribution, and consumption of goods and services when resources are limited and have alternative uses. At CDC, economics is used to systematically identify, measure, value, and compare the costs and consequences of alternative prevention strategies. Costs and consequences in public health can be measured in various ways, including incidence or prevalence of disease; numbers of adverse events; utility measures, such as quality-adjusted life years; and monetary values. Because it deals with behavior, economics is not really about money at all. Money is just a convenient way to measure incentives and consequences.

Centers for Disease Control and Prevention, U.S.↗

PubMed2005

Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.

OBJECTIVE: To evaluate the economic impact of the routine US childhood immunization schedule: diphtheria and tetanus toxoids and acellular pertussis; tetanus and diphtheria toxoids; Haemophilus influenzae type b conjugate; inactivated poliovirus; measles, mumps, and rubella; hepatitis B; and varicella vaccines. DESIGN: Decision tree-based analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported for 1995-2001. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and time lost. All costs were inflated to 2001 US dollars, and all costs and benefits in the future were discounted at a 3% annual rate. PARTICIPANTS: A hypothetical 2001 US birth cohort of 3,803,295 infants was followed up from birth through death. MAIN OUTCOME MEASURES: Net present value (net savings) and benefit-cost ratios of routine immunization. RESULTS: Routine childhood immunization with the 7 vaccines was cost saving from the direct cost and societal perspectives, with net savings of 9.9 billion dollars and 43.3 billion dollars, respectively. Without routine vaccination, direct and societal costs of diphtheria, tetanus, pertussis, H influenzae type b, poliomyelitis, measles, mumps, rubella, congenital rubella syndrome, hepatitis B, and varicella would be 12.3 billion dollars and 46.6 billion dollars, respectively. Direct and societal costs for the vaccination program were an estimated 2.3 billion dollars and 2.8 billion dollars, respectively. Direct and societal benefit-cost ratios for routine childhood vaccination were 5.3 and 16.5, respectively. CONCLUSION: Regardless of the perspective, the current routine childhood immunization schedule results in substantial cost savings.

Chickenpox↗

PubMed2004

Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti.

BACKGROUND: Lymphatic filariasis (LF) affects more than 120 million people worldwide. Efforts to eliminate this disease require sustained community participation. This study explores community valuation of LF elimination efforts by estimating household and community willingness to pay (WTP) for the prevention of transmission and treatment of filarial lymphedema in the community of Leogane, Haiti. METHODS: A contingent valuation survey was used to assess individual WTP for specific prevention and treatment interventions. A 2-dimensional Monte Carlo simulation was developed to estimate confidence limits in mean WTP and to generate a distribution of WTP for the community, accounting for uncertainty in regression coefficients and variability within the population. RESULTS: Mean WTP was estimated to be $5.57/month/household (95% CL: $4.76, $6.72) to prevent disease transmission, and $491/yr (95% CL: $377, $662) for treatment of lymphedema for one person. Based on the estimated distributions, 7% and 39% of households were not willing to pay for prevention and treatment, respectively. CONCLUSIONS: These results suggest that the majority of the community places a positive value on both prevention and treatment of LF. Mean WTP provides a useful monetary estimate of overall societal benefit of LF prevention and treatment programs. However, for interventions which require broad and sustained community participation, the lower end of the distribution of WTP has additional implications. Cost recovery policies may result in inadequate participation and longer program duration.

Journal Article↗

PubMed2004

Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale.

We argue that health programs are administered in settings that often violate the frequently stated assumption of constant returns to scale in the provision of health services. Three types of returns to scale are identified from the general economic literature: returns to scale with respect to population, effectiveness, and quality. We show that decision rules based on incremental cost-effectiveness ratios or cost-benefit tests are not optimal if returns to scale are not constant. We derive the optimal decision rules under variable returns to scale using optimization techniques, and employ several examples to illustrate the concepts and methods.

Cost-Benefit Analysis↗

PubMed2002

Disability and its economic impact among adults with diabetes.

The objective of this study was to estimate the annual cost of disability among people with diabetes. Data from the 1994 Behavioral Risk Factor Surveillance System (n = 83,566) of US individuals aged 18 to 64 years were used to estimate the annual cost of disability among people with self-reported diabetes. After we adjusted for relevant socioeconomic characteristics, logistic regression analyses demonstrated that people with diabetes are more likely to stop working outside the home (for men: adjusted odds ratio, 3.1; 95% confidence interval, 1.2 to 8.0; for women: adjusted odds ratio, 2.9; 95% confidence interval, 1.0 to 8.8). The annual cost of disability among people with diabetes was estimated at $9.3 billion in 1994. Disability among people with diabetes is a major public health problem. Efforts to reduce disability in this population could create substantial gains in productivity.

Activities of Daily Living↗